Form 4 holding
Director
IMMUNIC, INC.
- Security class
- Stock Option
- Shares / value
- 150,000
- Estimated value
- Report date
- 05 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Tamar D. Howson
Insider Reports History
- Latest reporting-owner signature
- /s/ Tamar Howson
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Tamar D. Howson
Form 4 holding
Director
IMMUNIC, INC.
- Security class
- Stock Option
- Shares / value
- 100,000
- Estimated value
- Report date
- 11 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Cue Biopharma, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 10,000
- Estimated value
- Report date
- 03 Jan 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
MEI Pharma, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 10,000
- Estimated value
- Report date
- 29 Sep 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Tamar D. Howson
4
IMUX
IMMUNIC, INC.
- Report period
- 05 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2025, 16:09
- Role
- Director
- Next action
- Open filing details
4
IMUX
IMMUNIC, INC.
- Report period
- 11 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2024, 16:05
- Role
- Director
- Next action
- Open filing details
4
IMUX
IMMUNIC, INC.
- Report period
- 04 Mar 2024
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 06 Mar 2024, 21:52
- Role
- Director
- Next action
- Open filing details
4
MEIP
MEI Pharma, Inc.
- Report period
- 29 Sep 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Oct 2023, 19:40
- Role
- Director
- Next action
- Open filing details
4
IMUX
IMMUNIC, INC.
- Report period
- 28 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 29 Jun 2023, 16:50
- Role
- Director
- Next action
- Open filing details
4
CUE
Cue Biopharma, Inc.
- Report period
- 03 Jan 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jan 2023, 15:09
- Role
- Director
- Next action
- Open filing details
4
MEIP
MEI Pharma, Inc.
- Report period
- 05 Jul 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 07 Jul 2022, 16:26
- Role
- Director
- Next action
- Open filing details
4
IMUX
IMMUNIC, INC.
- Report period
- 15 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2022, 21:31
- Role
- Director
- Next action
- Open filing details
4
CUE
Cue Biopharma, Inc.
- Report period
- 03 Jan 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jan 2022, 19:24
- Role
- Director
- Next action
- Open filing details
4
MEIP
MEI Pharma, Inc.
- Report period
- 01 Jul 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Jul 2021, 19:00
- Role
- Director
- Next action
- Open filing details
4
IMUX
IMMUNIC, INC.
- Report period
- 10 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2021, 17:02
- Role
- Director
- Next action
- Open filing details